Table 1.

Baseline characteristics of the MTX population and total trial participants

Parameter	MTX population (n=188)	Total trial participants (n=206)
Male sex, n (%)	100 (53.2)	108 (52·4)
Age (years), median (IQR)	44.5 (37.0, 52.0)	45 (38, 53)
Ethnicity: Caucasian, n (%)	171 (91.0)	188 (91·3)
Number of swollen joints (0-66), median (IQR)	5.0 (3.0, 9.0)	5·0 (2·0, 9·0)
Number of tender joints (0-68), median (IQR)	9.0 (3.5, 19.0	9·0 (4·0, 18·0)
CRP(mg/dl), median (IQR)	6.6 (5.0, 20.0)	6·7 (5·0, 18·2)
Rheumatoid factor negative, n (%)	177 (94.1)	195 (94·7)
CCP negative, n (%)	158 (84.0)	172 (83·5)
Early morning stiffness (EMS), n (%)	168 (89.4)	184 (89·3%)
EMS duration (hours), median (IQR) (patients with EMS)	1.0 (0.0, 2.0)	1·0 (0·5, 2·0)
Arthritis pattern, n (%) of patients
Polyarthritis (≥5 joints)	135 (71.8)	146 (70·9)
Oligoarthritis (<5 joints)	53 (28.2)	60 (29·1)
DIP disease	41 (21.8)	45 (21·8)
Axial involvement	42 (22.3)	43 (20·9)
Arthritis mutilans	0 (0.0)	0 (0·0)
CASPAR criteria met (score ≥3), n (%)	172 (91.5)	188 (91·3)
CASPAR score ≥2, n (%)	184 (97.9)	202 (98·1)
Current psoriasis, n (%)	159 (84.6)	174 (84·5)
PASI score (all patients), median (IQR)	2.0 (0.6, 4.2)	1·9 (0·6, 4·2)
PASI score (condition at baseline), median (IQR)	2.6 (1.2, 4.7)	2·6 (1·2, 4·8)
Current enthesitis, n (%)	148 (78.7)	162 (78·6)
Enthesitis score (all patients), median (IQR)	2.0 (1.0, 6.0)	2·0 (1·0, 6·0)
Enthesitis score (condition at baseline), median (IQR)	4.0 (2.0, 7.0)	4.0 (2·0, 7·0)
Current dactylitis, n (%)	59 (31.4)	62 (30·1)
Dactylitis score (all patients), median (IQR)	0.0 (0.0, 15.8)	0·0 (0·0, 13·0)
Dactylitis score (condition at baseline), median (IQR)	38.0 (20.0, 105.0)	37·0 (19·0, 96·0)
Current nail disease, n (%)	117 (62.2)	124 (60·2)
mNAPSI score (all patients), median (IQR)	2.0 (0.0, 11.8)	2·0 (0·0, 10·0)
mNAPSI score (condition at baseline), median (IQR)	8.0 (2.0, 20.0)	8·0 (2·0, 19·0)